-
Basel, June 17, 2022 - Novartis today announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manuscripts, reinforcing the transformational benefit of Zolgensma® (onasemnogene abeparvovec) when used early. These data demonstrate that, whether they…Rare DiseasesNeuroscienceCell and Gene Therapy
-
Basel, June 12, 2022 — Novartis today announced long-term results from the ELIANA pivotal clinical trial of Kymriah® (tisagenlecleucel), the first-ever approved CAR-T cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL), with a maximum survival follow-up of 5.9 years. For…OncologyCell and Gene TherapyCancer
-
Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. In accordance with the Accelerated Approval Program, …OncologyInnovationCell and Gene TherapyCancer
-
Inspired by Emily Whitehead, along with other early patients treated with CAR-T cell therapy, Novartis embarked on a pioneering journey to reimagine cancer treatment. After 10 years, we continue to relentlessly pursue new science around cell and gene therapies to transform the lives of patients today and in the future.
CancerCell and Gene TherapyChildren's HealthNovartis Institutes for BioMedical ResearchOncology -
Basel, May 4, 2022 — Novartis announced today that the European Commission (EC) has approved Kymriah® (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. The approval follows a positive opinion in March by the Committee…OncologyCell and Gene TherapyCancer
-
Basel, March 25, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the European Commission to approve Kymriah® (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r)…OncologyCell and Gene TherapyCancer
-
Basel, March 10, 2022 — Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.Global Health PartnershipsCell and Gene TherapyCancer
-
Basel, December 22, 2021 — Novartis announced today that it entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics.OphthalmologyFuture of HealthcareEye CareCell and Gene Therapy
-
Basel, December 13, 2021 — Novartis today announced the introduction of T-Charge™, the company’s next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. At the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) 2021, Novartis will…Reimagine MedicineMedical InnovationsCell and Gene Therapy
-
Basel, August 24, 2021 — Novartis today announced an update on the Phase III BELINDA study investigating Kymriah® (tisagenlecleucel) in aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment. The BELINDA study did not meet its primary endpoint of event-free survival compared to treatment with the…Cell and Gene TherapyCancer
-
Basel, 21. September 2021 — Novartis hat heute die Übernahme von Arctos Medical bekanntgegeben. Das Unternehmen erweitert dadurch sein Portfolio in der Augenheilkunde um das präklinische AAV*-Gentherapieprogramm sowie die entsprechende Technologie von Arctos. Die Übernahme unterstreicht das Engagement von Novartis, Behandlungsmöglichkeiten für…OphthalmologyEye CareCell and Gene Therapy
-
Bâle, le 21 septembre, 2021 — Novartis a annoncé aujourd’hui avoir acquis Arctos Medical, ajoutant à son portefeuille d’ophtalmologie un programme préclinique de thérapie génique AAV basé sur l’optogénétique et la technologie exclusive d’Arctos. Cette acquisition souligne l’engagement de Novartis dans la recherche de traitements pour les patients…OphthalmologyEye CareCell and Gene Therapy
-
Inspired by Emily Whitehead, along with other early patients treated with CAR-T cell therapy, Novartis embarked on a pioneering journey to reimagine cancer treatment. After 10 years, we continue to relentlessly pursue new science around cell and gene therapies to transform the lives of patients today and in the future.